

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/35987 A1

- (51) International Patent Classification⁷: A61K 38/21, 9/08
- (21) International Application Number: PCT/KR00/01322
- (22) International Filing Date:
17 November 2000 (17.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
1999/51481 19 November 1999 (19.11.1999) KR
- (71) Applicant (for all designated States except US): LG CHEMICAL LTD. [KR/KR]; 20, Yoido-dong, Young-dungpo-ku, Seoul 150-721 (KR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KANG, Young, Cheol [KR/KR]; #7-204, 386-42 LG Chemical Apt., Doryong-dong, Yusong-ku, Taejon-si 305-340 (KR). LEE, Sang-Heon [KR/KR]; #6-1305 Kumho Apt., Chungchon-dong, Chung-ku, Taejon-si 301-080 (KR). HAN, Kyuboem [KR/KR]; #102-1002 Lucky-Hana Apt., Shinsung-dong, Yusong-ku, Taejon-si 305-345 (KR).
- (74) Agents: CHOI, Sung, Min et al.; Samdo Bldg. 4th Floor, 1-170 Soonhwa-dong, Chung-ku, Seoul 100-130 (KR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AN AQUEOUS SOLUTION FORMULATION OF ALPHA-INTERFERON



(57) Abstract: The present invention relates to an aqueous solution formulation which can retain the biological activity and physicochemical properties of α -interferon for a long period. More particularly, the present invention relates to an aqueous solution formulation of α -interferon comprising α -interferon; a stabilizer; an osmotic pressure regulating agent; antimicrobial preservatives selected from the group consisting of phenol, m-cresol or mixture thereof; and a buffer system. The aqueous solution formulation of the present invention has many advantages because it retains the activity of α -interferon for a long period, eliminates potential harmfulness to human body by minimizing the amount of the preservatives, and is very stable.

WO 01/35987 A1

What is claimed is;

1. An aqueous solution formulation of α -interferon comprising α -interferon; a stabilizer; an osmotic pressure regulating agent; antimicrobial preservatives
5 selected from the group consisting of phenol, m-cresol or mixture thereof ; and a buffer system.
2. The aqueous solution formulation of α -interferon according to Claim 1, wherein the amount of α -interferon added is in the range of 1×10^6 IU/ml $\sim 1 \times 10^8$ IU/ml.
- 10 3. The aqueous solution formulation of α -interferon according to Claim 1, wherein the stabilizer is polysorbate 80.
4. The aqueous solution formulation of α -interferon according to Claim 3, wherein the concentration of polysorbate 80 is in the range of 0.01 \sim 0.05 w/v %.
- 15 5. The aqueous solution formulation of α -interferon according to Claim 1, wherein the osmotic pressure regulating agent is sodium chloride.
6. The aqueous solution formulation of α -interferon according to Claim 1, wherein the preservative is selected from the group consisting of 0.1 \sim 0.3 w/v % phenol, 0.1 \sim 0.2 w/v % m-cresol, or mixture thereof.
- 20 7. The aqueous solution formulation of α -interferon according to Claim 1, wherein the buffer system is a buffer system consisting of ammonium acetate and acetic acid; or a buffer system consisting of sodium monohydrogen phosphate (Na_2HPO_4) and sodium dihydrogen phosphate (NaH_2PO_4).
8. The aqueous solution formulation of α -interferon according to Claim 7,

wherein the concentration of the buffer system in the aqueous solution formulation is in the range of 5 ~ 20 mM.

9. The aqueous solution formulation of α -interferon according to Claim 1, wherein the pH of the formulation is in the range of 4.5 ~ 6.0.

